AVIR
Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
+0.52%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+36.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | Berman Howard · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | Murphy Polly A. · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | Adams Jerome M. · director | M-Exempt | 29,600 | $0.00 |
| Jun 23, 2026 | Adams Jerome M. · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | Adams Jerome M. · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | KIRSCH ARTHUR S · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | KIRSCH ARTHUR S · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | Murphy Polly A. · director | M-Exempt | 29,600 | $0.00 |
| Jun 23, 2026 | Berman Howard · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | BERGER FRANKLIN M · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | BERGER FRANKLIN M · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | BERGER FRANKLIN M · director | M-Exempt | 29,600 | $0.00 |
| Jun 23, 2026 | Lucidi Bruno · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | Lucidi Bruno · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | Lucidi Bruno · director | M-Exempt | 29,600 | $0.00 |
| Jun 23, 2026 | DUNCAN BARBARA GAYLE · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | DUNCAN BARBARA GAYLE · director | M-Exempt | 29,600 | $0.00 |
| Jun 23, 2026 | Murphy Polly A. · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | Polsky Bruce · director | A-Award | 37,700 | $4.36 |
| Jun 23, 2026 | Polsky Bruce · director | A-Award | 26,700 | $0.00 |
| Jun 23, 2026 | Polsky Bruce · director | M-Exempt | 29,600 | $0.00 |
| Jun 23, 2026 | DUNCAN BARBARA GAYLE · director | A-Award | 37,700 | $4.36 |
| May 21, 2026 | Murphy Polly A. · director | Purchase | 6,100 | $4.17 |
| May 20, 2026 | Murphy Polly A. · director | Purchase | 6,100 | $4.17 |
| Mar 13, 2026 | Corcoran Andrea · officer: See Remarks | M-Exempt | 60,000 | $1.24 |
| Feb 3, 2026 | Hammond Janet MJ · officer: Chief Development Officer | M-Exempt | 58,050 | $0.00 |
| Feb 3, 2026 | Sommadossi Jean-Pierre · director, officer: President, CEO, and Chairman | M-Exempt | 272,983 | $0.00 |
| Feb 3, 2026 | Sommadossi Jean-Pierre · director, officer: President, CEO, and Chairman | F-InKind | 106,093 | $4.24 |
| Feb 3, 2026 | Sommadossi Jean-Pierre · director, officer: President, CEO, and Chairman | M-Exempt | 99,517 | $0.00 |
| Feb 3, 2026 | Foster Wayne · officer: EVP, Chief Accounting Officer | A-Award | 108,000 | $4.24 |
Institutional positioning
13F filings over the trailing two quarters
New 48Increased 83Reduced 80Sold out 20
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 12,004,064 | Aug 13, 2026 |
| FMR LLC | Increased | 11,950,772 | May 15, 2026 |
| BlackRock, Inc. | Increased | 8,720,077 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 8,435,437 | May 13, 2026 |
| BML CAPITAL MANAGEMENT, LLC | Reduced | 7,058,657 | May 6, 2026 |
| BML Capital Management, LLC | Reduced | 6,952,330 | Aug 7, 2026 |
| TANG CAPITAL MANAGEMENT LLC | Unchanged | 4,814,700 | May 15, 2026 |
| TANG CAPITAL MANAGEMENT LLC | Unchanged | 4,814,700 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,246,124 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 2,964,862 | Aug 13, 2026 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Reduced | 2,360,638 | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | Reduced | 2,075,639 | Aug 14, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | Increased | 2,035,192 | Aug 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 1,958,435 | Aug 12, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 1,864,164 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 23, 2026